A groundbreaking study led by researchers in Finland has uncovered a profound and previously underestimated link between frontotemporal dementia (FTD) and epileptic seizures. The research, which represents one of the most comprehensive datasets of its kind globally, suggests that epilepsy is far more common in patients suffering from this specific form of memory disorder than the medical community had previously recognized. This discovery not only deepens the scientific understanding of the complex symptomatic profile of FTD but also highlights a critical need for revised protocols in the clinical monitoring and long-term treatment of patients.
The project was a collaborative effort coordinated by Neurocenter Finland, bringing together the expertise of the University of Eastern Finland and the University of Oulu. By analyzing a massive repository of real-world patient data, the research team was able to provide a clearer picture of the neurological landscape of FTD. The findings, which have significant implications for both diagnostic accuracy and patient quality of life, were recently published in the prestigious medical journal JAMA Neurology.
Frontotemporal dementia is a group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain—areas generally associated with personality, behavior, and language. Unlike Alzheimer’s disease, which typically presents with memory loss as its earliest and most prominent symptom, FTD often manifests through dramatic changes in social conduct, emotional regulation, or communication abilities. Because the symptoms are so distinct, the discovery that epilepsy plays a major role in the disease’s progression adds a new layer of complexity to how the condition must be managed.
Epilepsy occurred years before the FTD diagnosis
One of the most striking revelations of the study is the timeline in which epilepsy appears. While it has long been established that epilepsy is a common comorbidity in Alzheimer’s disease, data regarding its connection to frontotemporal dementia has historically been scarce and inconsistent. This lack of information has often left clinicians without clear guidance on how to screen for or treat seizures in FTD populations.
To fill this information gap, the research team conducted an exhaustive analysis of medical records from the university hospitals of Kuopio and Oulu, covering the period between 2010 and 2021. The sheer scale of the study is notable: researchers screened 12,490 medical records to identify a cohort of 245 patients with FTD and 1,326 patients with Alzheimer’s disease. These groups were then compared against healthy controls to determine the relative prevalence of epilepsy across different neurological profiles.
The results were definitive. "Our results show that epilepsy is considerably more common among those with FTD than those with Alzheimer’s disease or in healthy controls," stated Doctoral Researcher Annemari Kilpeläinen, the lead author of the study and a medical specialist in neurology. This finding challenges the traditional hierarchy of dementia-related comorbidities, placing FTD at the forefront of concern regarding seizure activity.
Perhaps more startling was the timing of these seizures. The data revealed that in several instances, epilepsy was diagnosed as many as ten years before the patient received a formal diagnosis of frontotemporal dementia. This suggests that for some patients, epileptic activity may be one of the earliest indicators of the underlying neurodegenerative processes that eventually lead to FTD.
